Ophthalmology News and Research

RSS

Ophthalmology is the specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology and diseases that may affect the eye. Historically, the science of ophthalmology encompassed all aspects of visual function, both in health and in illness. Additionally, ophthalmology also includes animal eyes as ocular function and optic diseases are similar among humans and animals.

NovaBay to present data on Aganocide compounds at ARVO annual meeting

NovaBay Pharmaceuticals, Inc. announced today that the latest public data on its Aganocide® compounds, a new class of broad-spectrum antimicrobials, will be presented during three poster sessions at the Association for Research in Vision and Ophthalmology annual meeting in Fort Lauderdale, Florida.

30 Apr 2010

Nationwide Children's Hospital opens first pediatric Pseudotumor Cerebri Clinic in the U.S.

While most headaches in children can be treated with over-the-counter pain medications or lifestyle changes, it is important to pay attention to their symptoms in case they herald something more serious.

30 Apr 2010

New tool to detect inflammatory eye disease at molecular level before damage occurs

Forget what you know about how diseases are diagnosed-new research published in the May 2010 print issue of The FASEB Journal details a noninvasive ground-breaking tool that detects signs of disease at early molecular stages before symptoms can be seen using traditional methods.

30 Apr 2010

pSivida receives full payment of $15M note from Alimera Sciences

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).

29 Apr 2010

SurModics reports second-quarter GAAP revenue of $18.4 million, up 6% sequentially

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the second quarter ended March 31, 2010.

29 Apr 2010

Researchers participate in national multi-center trial comparing treatments for diabetic macular edema

A drug may be more effective against the leading cause of adult blindness than laser treatments, a new study has shown.

28 Apr 2010

Ranibizumab eye injections plus laser therapy result in dramatic visual improvement

Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina.

28 Apr 2010

DRCR Network study finds new treatment more effective

28 Apr 2010

Better vision ahead for many diabetic retinopathy patients

A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.

27 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

Advanced Cell Technology, Inc. announced today that it has completed key animal studies in connection with its Phase I multicenter study using embryonic stem cell derived Retinal Pigment Epithelium (RPE) cells to treat patients with Stargardt's Macular Dystrophy (SMD), for which it filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) in November. The studies demonstrated an excellent safety profile with no safety signals such as tumors or ectopic tissues.

24 Apr 2010

New gene therapy to restore retinal cone function and day vision

Veterinary ophthalmology researchers from the University of Pennsylvania have used gene therapy to restore retinal cone function and day vision in two canine models of congenital achromatopsia, also called rod monochromacy or total color blindness.

22 Apr 2010

IP Advocate founder settles long-standing legal battle with UGARF

In a move that positions IP Advocate for its next chapter as a champion of research translation, founder Dr. Renee Kaswan today announced that she has settled her long-standing legal battle with the University of Georgia Research Foundation.

21 Apr 2010

Effects of UV radiation may increase chance of developing eye problems later in life

While 85 percent of Americans recognize that ultraviolet rays can damage their eyes, only 65 percent wear sunglasses as protection, and even fewer (39 percent) make sure their children wear sunglasses. By comparison, 78 percent make sure their children wear sunscreen when outdoors.

21 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Minnesota OMC's $20.9M series 2010 revenue bonds rated 'BBB-' by Fitch

Fitch Ratings assigns a 'BBB-' rating to the following City of Rochester, Minnesota health care facilities revenue bonds: --$20.9 million series 2010 revenue bonds (Olmsted Medical Center Project).

17 Apr 2010

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

16 Apr 2010

Ophthalmology News and Research

Further Reading

NovaBay to present data on Aganocide compounds at ARVO annual meeting

Nationwide Children's Hospital opens first pediatric Pseudotumor Cerebri Clinic in the U.S.

New tool to detect inflammatory eye disease at molecular level before damage occurs

pSivida receives full payment of $15M note from Alimera Sciences

SurModics reports second-quarter GAAP revenue of $18.4 million, up 6% sequentially

Researchers participate in national multi-center trial comparing treatments for diabetic macular edema

Ranibizumab eye injections plus laser therapy result in dramatic visual improvement

DRCR Network study finds new treatment more effective

Better vision ahead for many diabetic retinopathy patients

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

New gene therapy to restore retinal cone function and day vision

IP Advocate founder settles long-standing legal battle with UGARF

Effects of UV radiation may increase chance of developing eye problems later in life

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

Minnesota OMC's $20.9M series 2010 revenue bonds rated 'BBB-' by Fitch

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Spring is busting out all over - and so are eye allergies

eRNA molecules are key players in brain development, says study

Ophthalmologist implants radioactive discs in the eyes of children with rare cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News